Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

02 avr. 2025 08h37 HE | Source: Research and Markets

STAT3 Inhibitors Market Analysis & Clinical Trials Report 2025-2028: Innovation in Drug delivery and Formulation Techniques - Opportunities May Expand Beyond Oncology

Dublin, April 02, 2025 (GLOBE NEWSWIRE) -- The "STAT3 Inhibitors Market Opportunity & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering. The market for...
02 juin 2023 05h03 HE | Source: Research and Markets

Global STAT3 Inhibitors Market & Clinical Trials Outlook Report 2023-2028: Insights by Country, Indication, Organization & Phase

Dublin, June 02, 2023 (GLOBE NEWSWIRE) -- The "Global STAT3 Inhibitors Market & Clinical Trials Outlook 2028" report has been added to ResearchAndMarkets.com's offering. The dysregulation of...
27 janv. 2023 04h58 HE | Source: Research and Markets

Global STAT3 Inhibitors Market & Clinical Trials Outlook 2028: FDA and EMA Special Drug Designations to Ignite R&D Progress

Dublin, Jan. 27, 2023 (GLOBE NEWSWIRE) -- The "Global STAT3 Inhibitors Market & Clinical Trials Outlook 2028" report has been added to ResearchAndMarkets.com's offering. The dysregulation of...
20 déc. 2021 06h58 HE | Source: Research and Markets

Global Stat Inhibitors Pipeline Landscape 2021 Featuring Over 25 Drugs and Companies, Including Bio-Path, Jiangsu Hengrui Medicine Co, Reata Pharmaceuticals, Tvardi Therapeutics, and Purple Biotech

Dublin, Dec. 20, 2021 (GLOBE NEWSWIRE) -- The "Stat Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering. This report provides comprehensive...